Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The facility features 2,176 high-performance GPUs across the US and Europe
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The initiative comes through a collaboration with Asia’s oldest latex condom manufacturer
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
Subscribe To Our Newsletter & Stay Updated